Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Regeneron Pharmaceuticals, Inc. (REGN), featuring income statements, balance sheets, and cash flow data.
Regeneron Pharmaceuticals, Inc. (REGN) Income Statement & Financial Overview
Review Regeneron Pharmaceuticals, Inc. REGN income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.03B | $3.79B | $3.72B | $3.55B |
| Cost of Revenue | $464.30M | $565.40M | $491.10M | $600.90M |
| Gross Profit | $2.56B | $3.22B | $3.23B | $2.95B |
| Gross Profit Ratio | $0.85 | $0.85 | $0.87 | $0.83 |
| R&D Expenses | $1.34B | $1.41B | $1.27B | $1.08B |
| SG&A Expenses | $633.00M | $792.20M | $714.40M | $758.80M |
| Operating Expenses | $1.97B | $2.23B | $2.05B | $1.85B |
| Total Costs & Expenses | $2.17B | $2.80B | $2.54B | $2.45B |
| Interest Income | $0.00 | $183.10M | $187.40M | $179.40M |
| Interest Expense | $0.00 | $10.50M | $13.80M | $14.80M |
| Depreciation & Amortization | $126.90M | $126.40M | $121.70M | $120.70M |
| EBITDA | $1.04B | $1.09B | $1.63B | $1.21B |
| EBITDA Ratio | $0.34 | $0.29 | $0.44 | $0.34 |
| Operating Income | $591.70M | $990.20M | $1.18B | $1.09B |
| Operating Income Ratio | $0.20 | $0.26 | $0.32 | $0.31 |
| Other Income/Expenses (Net) | $313.30M | -$32.10M | $313.50M | $558.50M |
| Income Before Tax | $905.00M | $958.10M | $1.49B | $1.63B |
| Income Before Tax Ratio | $0.30 | $0.25 | $0.40 | $0.46 |
| Income Tax Expense | $96.30M | $40.40M | $152.40M | $195.80M |
| Net Income | $808.70M | $917.70M | $1.34B | $1.43B |
| Net Income Ratio | $0.27 | $0.24 | $0.36 | $0.40 |
| EPS | $7.58 | $8.53 | $12.40 | $13.25 |
| Diluted EPS | $7.27 | $8.06 | $11.54 | $12.41 |
| Weighted Avg Shares Outstanding | $106.70M | $107.90M | $108.10M | $108.10M |
| Weighted Avg Shares Outstanding (Diluted) | $111.20M | $115.10M | $116.20M | $115.40M |
Over the last four quarters, Regeneron Pharmaceuticals, Inc. achieved steady financial progress, growing revenue from $3.55B in Q2 2024 to $3.03B in Q1 2025. Gross profit stayed firm with margins at 85% in Q1 2025 versus 83% in Q2 2024. Operating income totaled $591.70M in Q1 2025, maintaining a 20% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $1.04B. Net income dropped to $808.70M, with EPS at $7.58. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan